Oncopeptides AB (publ)
ONPPF · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $13,267 | $9,914 | $8,507 | $8,155 |
| % Growth | 33.8% | 16.5% | 4.3% | – |
| Cost of Goods Sold | -$85 | $727 | $701 | $947 |
| Gross Profit | $13,351 | $9,187 | $7,806 | $7,208 |
| % Margin | 100.6% | 92.7% | 91.8% | 88.4% |
| R&D Expenses | $28,727 | $43,150 | $21,932 | $27,860 |
| G&A Expenses | $16,811 | $8,102 | $18,368 | $16,428 |
| SG&A Expenses | $45,300 | $50,811 | $48,196 | $52,613 |
| Sales & Mktg Exp. | $28,489 | $42,709 | $29,828 | $36,185 |
| Other Operating Expenses | -$840 | -$1,440 | -$1,071 | -$1,014 |
| Operating Expenses | $73,187 | $92,521 | $69,057 | $79,459 |
| Operating Income | -$59,835 | -$83,334 | -$61,251 | -$72,251 |
| % Margin | -451% | -840.6% | -720% | -886% |
| Other Income/Exp. Net | -$788 | $697 | $651 | -$971 |
| Pre-Tax Income | -$60,623 | -$82,637 | -$60,600 | -$73,222 |
| Tax Expense | $46 | $789 | -$366 | $22 |
| Net Income | -$60,669 | -$83,426 | -$60,233 | -$73,243 |
| % Margin | -457.3% | -841.5% | -708% | -898.1% |
| EPS | -0.28 | -0.39 | -0.39 | -0.48 |
| % Growth | 28.2% | 0% | 18.7% | – |
| EPS Diluted | -0.28 | -0.39 | -0.39 | -0.48 |
| Weighted Avg Shares Out | 213,913 | 213,913 | 152,590 | 152,590 |
| Weighted Avg Shares Out Dil | 213,913 | 213,913 | 152,590 | 152,590 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $697 | $652 | $29 |
| Interest Expense | $788 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$1,000 |
| EBITDA | -$59,835 | -$83,334 | -$61,251 | -$73,251 |
| % Margin | -451% | -840.6% | -720% | -898.2% |